



MYPERIOD[®] IL-6

SAMPLE, REPORT

Date of Birth: 01/01/1975 (48 yrs)

Gender: Female

Patient ID: 920-I

Patient Location: Test Site A

ORDERING PROVIDER

Ronald McGlennen MD
7400 Flying Cloud Drive
Suite 150
Eden Prairie, MN 55344
855-672-5362

SAMPLE INFORMATION

Specimen#: 5989009009

Accession#: 202306-03373

Specimen: Oral Rinse(P)

Collected: 06/17/2023

Received: 06/17/2023 23:00

Reported: 06/19/2023 11:30



ORALDNA[®] LABS

7400 Flying Cloud Drive
Suite 150
Eden Prairie, MN 55344

Phone: 855-672-5362
Fax: 952-942-0703

oraldna.com

CLIA#: 24D1033809
CAP#: 7190878

Sample, Report

Date of Birth: 01/01/1975 (48 yrs)
Gender: Female
Patient ID: 92O-I
Patient Location: Test Site A

Ordering Provider

Ronald McGlennen MD
7400 Flying Cloud Drive
Suite 150
Eden Prairie, MN 55344
855-672-5362

Specimen#: 5989009009
Accession#: 202306-O3373
Specimen: Oral Rinse(P)
Collected: 06/17/2023
Received: 06/17/2023 23:00
Reported: 06/19/2023 11:30

Reason for Testing New Patient
Related Info Not Provided
Patient History Current Smoker, Past History of Smoking

MYPERIODID® MOLECULAR DETECTION OF IL-6 PERIODONTAL RISK FACTORS

Genotype	Risk
C/C	LOW

Interpretation:

This individual's interleukin 6 genotype (IL-6) is C/C. The MyPeriodID result indicates your patient does not have an increased risk for periodontal inflammation due to the genetic variation examined in this test.

Significance:

This individual's (IL-6) genotype is C/C and therefore is not at increased risk for periodontal disease by overproduction of (IL-6) cytokine in the presence of bacteria. This individual's result does not rule out all risk for periodontal disease.

Risk:


Studies demonstrate that carriers of the 'C' allele are significantly less affected by periodontal disease when compared with carriers of the 'G' allele. However, some patients may be MyPeriodID low risk and have periodontal disease due to other risk factors.

Consider:

IL-6 is a potent stimulator of osteoclast differentiation and bone resorption, is an inhibitor of bone formation, and overproduction of IL-6 has been implicated in systemic diseases such as juvenile chronic arthritis, rheumatoid arthritis, osteoporosis, Paget's disease, and Sjogren's syndrome. The MyPeriodID test assesses one of several risk factors that should be included in an overall evaluation of periodontal disease. Specific bacteria are associated with IL-6 initiation of the periodontal disease. Additional risk factors, including other genetic markers, smoking, diabetes, and oral hygiene, have an amplifying effect on disease progression and duration. The incidence of IL-6 genotypes is reported to vary by ethnicity. Additional testing, such as MyPerioPath, may be considered if not already performed.

Methodology: Genomic DNA is extracted and tested for the interleukin 6 genetic variation located at position -174 (rs1800795). This genetic variation is tested by methods of the polymerase chain reaction, endonuclease digestion and resultant restriction fragment detection by automated microcapillary electrophoresis.

Disclaimer: The reported genotypes are a subset of the group of genes that comprise the complete immune system. This genetic analysis may not detect specific immunologic diseases or predict the health and effectiveness of a person's immunity for specific diseases. Such an evaluation may require genetic counseling and testing directed to characterize those genetic conditions. The analytical and performance characteristics of this laboratory-developed test (LDT) was determined by OralDNA Labs pursuant to Clinical Laboratory Improvement Amendments (CLIA 88) requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.



Ronald McGlennen MD, FCAP, FACMG, ABMG
Medical Director

